HLY78|cas:854847-61-3|西域试剂

HLY78,98.49%

产品编号：Bellancom-122816| CAS NO：854847-61-3| 分子式：C₁₇H₁₇NO₂| 分子量：267.32

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-122816	￥1200.00	杭州北京（现货）
Bellancom-122816	￥2000.00	杭州北京（现货）
Bellancom-122816	￥4000.00	杭州北京（现货）
Bellancom-122816	￥6400.00	杭州北京（现货）
Bellancom-122816	￥9600.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

HLY78

产品介绍

HLY78 是 Lycorine (HY-N0288) 衍生物，是一种有效的 Wnt/β-catenin 信号通路的激活剂。HLY78 靶向于 Axin 的 DIX 结构域，促进 Axin-LRP6 的关联，从而促进 LRP6 磷酸化 (LRP6 phosphorylation) 和 Wnt 信号转导。HLY78 可用于蛛网膜下腔出血 (SAH) 的研究。

生物活性

HLY78, a Lycorine (HY-N0288) derivative, is a potent activator of the Wnt/β-catenin signaling pathway. HLY78 targets the DIX domain of Axin and promotes the Axin-LRP6 (lipoprotein receptor-related protein 6) association, thus promoting LRP6 phosphorylation and Wnt signal transduction. HLY78 can be used for subarachnoid hemorrhage (SAH) research.

体外研究

HLY78 inhibits apoptosis in tumor cells and embryonic cells caused by carbon ion radiation through activation of the Wnt/β-catenin pathway.
HLY78 (20 μM, 0-48 h) significantly increases the colony formation ability by 2.78-fold and 2.88-fold for HGC-27 and AGS cells compared with the controls.
HLY78 (20 μM, 0-48 h) elevates the migration ability of HGC-27 and AGS cells.
HLY78 significantly increases TNKS expression, which is ameliorated by Dihydroartemisinin (HY-N0176).

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

HLY78 (0-1.8 mg/kg, Intranasal injection, once) attenuates neuronal apoptosis and improves neurological deficits through the LRP6/GSK3β/β-catenin signaling pathway after SAH (subarachnoid hemorrhage) in rats.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Adult male Sprague-Dawley rats (280-310 g, n=9/group, SAH model)
Dosage:	0, 0.2, 0.6, and 1.8 mg/kg
Administration:	Intranasal injection, once, at 1 h post-SAH (subarachnoid hemorrhage)
Result:	Significantly attenuated the short-term and long-term neurobehavioral deficits, as well as the neuronal apoptosis after SAH at 0.6 mg/kg. Successfully delivered into the brain via intranasal administration at 0.6 mg/kg and was sufficient to significantly increase the phosphorylation of LRP6. Reversed the changes of the Bcl-2, Bax, and cleaved caspase 3 levels.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Adult male Sprague-Dawley rats (280-310 g, n=9/group, SAH model)
Dosage:	0, 0.2, 0.6, and 1.8 mg/kg
Administration:	Intranasal injection, once, at 1 h post-SAH (subarachnoid hemorrhage)
Result:	Significantly attenuated the short-term and long-term neurobehavioral deficits, as well as the neuronal apoptosis after SAH at 0.6 mg/kg. Successfully delivered into the brain via intranasal administration at 0.6 mg/kg and was sufficient to significantly increase the phosphorylation of LRP6. Reversed the changes of the Bcl-2, Bax, and cleaved caspase 3 levels.

性状

Solid

溶解性数据

In Vitro:

DMSO : 26 mg/mL (97.26 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.7408 mL	18.7042 mL	37.4083 mL
5 mM	0.7482 mL	3.7408 mL	7.4817 mL
10 mM	0.3741 mL	1.8704 mL	3.7408 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式